The trade-off between the recurrence risk of a given HER2-positive BC versus the patient’s re-exposure cardiac risk to anti-HER2 treatment following the recovery from an asymptomatic LVEF dysfunction or mildly symptomatic CE must be taken into account: albeit a minority (30%) will develop a second LVEF drop to less than 50%, this incidence seems higher than what is seen for a first CE. Here, ERBB2 is linked to cholesteryl ester measurement.